MK-7264
MK-7264(英語:Gefapixant)是一种磺胺类药物,作为嘌呤P2X受体P2RX3的拮抗剂,可用于治疗慢性咳嗽[1][2][3]。
![]() | |
法律規範狀態 | |
---|---|
法律規範 |
|
识别信息 | |
| |
CAS号 | 1015787-98-0 ![]() |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.258.106 |
化学信息 | |
化学式 | C14H19N5O4S |
摩尔质量 | 353.4 |
3D模型(JSmol) | |
| |
|
参考文献
- ^ Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulmonary Pharmacology & Therapeutics. June 2019, 56 ( ): 75–78. PMID 30880151. doi:10.1016/j.pupt.2019.03.006.
- ^ Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. British Journal of Pharmacology. July 2019, 176 (13): 2279–2291. PMC 6555852 . PMID 30927255. doi:10.1111/bph.14677.
- ^ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. December 2019, 29 (12): 943–963. PMID 31726893. doi:10.1080/13543776.2019.1693542.
这是一篇關於呼吸系統的藥理學小作品。您可以通过编辑或修订扩充其内容。 |